Zheng F M, Fu H X, Han T T, Wang F R, Wang J Z, Chen Y, Yan C H, Zhang Y Y, Han W, Chen Y Y, Chen H, Wang Y, Zhang X H, Liu K Y, Huang X J, Xu L P
Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
Zhonghua Xue Ye Xue Za Zhi. 2017 Aug 14;38(8):656-661. doi: 10.3760/cma.j.issn.0253-2727.2017.08.002.
To compare incidence and clinical features of hemorrhage cystitis (HC) after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (HSCT) and matched sibling donor (MSD) HSCT. Medical records of 609 (including 406 HID-HSCT and 203 MSD-HSCT cases) hematologic malignancies patients treated with HSCT undergoing myeloablative conditioning regimen from January 2011 to December 2012 were analyzed retrospectively. HC occurred 183 in HID and 17 ones in MSD respectively. The cumulative incidence of HC in HID group was higher than in MSD group[ (45.6±2.5) % (8.5±2.0) %, (2)=77.331, <0.001], and the cumulative incidence of severe HC (grade 3-4) in HID cases was also higher than in MSD ones[ (11.2±1.9) % (2.1±1.1) %, (2)=12.883, <0.001]. All HCs were occurred within 180 days in both groups. The median time to onset in two groups were 27 days after HSCT (range 0-177 days) and 29 days after HSCT (range 6-72 days) respectively (=0.766) . The median duration of HC in two groups were 21 days (range 3-157 days) and 13 days (range 5-67 days) , respectively (=0.182) . The total efficiency of treatment in two groups were 69.9% and 70.6% respectively ((2)=0.003, =1.000) . The cumulative incidences of HC and severe HC were higher in HID cases than in MSD ones. The median time to onset and median duration of HC and therapeutic outcome between HID and MSD were comparable.
比较单倍体相合供者(HID)异基因造血干细胞移植(HSCT)和同胞全相合供者(MSD)HSCT后出血性膀胱炎(HC)的发生率及临床特征。回顾性分析2011年1月至2012年12月期间接受清髓性预处理方案的609例血液系统恶性肿瘤患者(包括406例HID-HSCT和203例MSD-HSCT病例)的病历。HID组发生HC 183例,MSD组发生17例。HID组HC的累积发生率高于MSD组[(45.6±2.5)% 对(8.5±2.0)%,χ²=77.331,P<0.001],HID组严重HC(3-4级)的累积发生率也高于MSD组[(11.2±1.9)% 对(2.1±1.1)%,χ²=12.883,P<0.001]。两组所有HC均发生在180天内。两组的中位发病时间分别为HSCT后27天(范围0-177天)和HSCT后29天(范围6-72天)(Z=0.766)。两组HC的中位持续时间分别为21天(范围3-157天)和13天(范围5-67天),(Z=0.182)。两组的总治疗有效率分别为69.9%和70.6%(χ²=0.003,P=1.000)。HID组HC和严重HC的累积发生率高于MSD组。HID组和MSD组HC的中位发病时间、中位持续时间及治疗结果相当。